LSTA
No price yet
Announcements
Nothing here yet
Daily updates
- Lisata Therapeutics secured a new U.S. method-of-use patent for certepetide in combination with anticancer treatments for pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant disease.Oct 10, 2026
- Lisata's subsidiary Marea Therapeutics dosed the first patient in a Phase 2 MAR002 trial for acromegaly, advancing a 72-patient study focused on IGF-1 reduction.Oct 5, 2026
FDA designations
Nothing here yet
News
- Lisata Therapeutics receives a new method-of-use patent for certepetide in pancreatic cancer and other solid tumorsOct 8, 2026
- Marea Therapeutics, a subsidiary of Lisata Therapeutics, doses the first patient in a Phase 2 trial of MAR002 for acromegalyOct 5, 2026
- Lisata Therapeutics and Catalent announce global antibody-drug conjugate (ADC) license agreementOct 9, 2025
- Lisata Therapeutics announces encouraging preliminary results from pancreatic cancer cohort of CENDIFOX trialSep 29, 2025